4/16/2021  9:59:56 PM Chg. -2.68 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
399.13USD -0.67% 63,609
Turnover: 25.19 mill.
-Bid Size: - -Ask Size: - 58.65 bill.USD 0.00% 89.06

Business description

Illumina is improving human health by unlocking the power of the genome. The company's focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Illumina's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.
 

Management board & Supervisory board

CEO
Francis deSouza
Management board
Sam A. Samad, Aimee Hoyt, Bob Ragusa, Charles Dadswell, Dr. Alex Aravanis, Dr. Joydeep Goswami, Dr. Mostafa Ronaghi, Dr. Phil Febbo, Gretchen Weightman, Jacquie Ross, Juliet Cunningham, Kathryne Reeves, Li Qing, Mark Van Oene, Nicole Berry, Paula Dowdy, Susan Tousi
Supervisory board
Jay T. Flatley (bis 26.05.2021), Caroline Dorsa, Dr. Frances Arnold, Francis A. deSouza, Gary S. Guthart, John W. Thompson (Chairman ab 26.05.2021), Philip W. Schiller, Robert S. Epstein, Scott Gottlieb, Susan E. Siegel
 

Company data

Name: Illumina Inc.
Address: 5200 Illumina Way,San Diego, California 92122, USA
Phone: +1-858-202-4500
Fax: +1-858-202-4545
E-mail: info@illumina.com
Internet: www.illumina.com/
Industry: Healthcare
Sector: Medical Products
Sub sector: Advanced Medical Devices
End of financial year: 12/31
Free Float: 67.10%
IPO date: -

Investor relations

Name: Juliet Cunningham
IR phone: +1-858-882-2172
IR Fax: -
IR e-mail: ir@illumina.com

Main Shareholders

Freefloat
 
67.10%
Baillie Gifford & Co.
 
12.10%
The Vanguard Group, Inc.
 
7.80%
BlackRock Inc.
 
7.60%
Capital Research Global Investors
 
5.40%
Others
 
0.00%